Tolerability Data for Shire's CUVITRU Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting

LEXINGTON, Massachusetts, November 12, 2016 /PRNewswire/ -- Data reveals key findings on the tolerability of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] for patients, regardless of treatment infusion volume and rates Shire plc (LSE: SHP, NASDAQ: SHPG) will...